A higher drug dose helped control brain spots in a woman with lung cancer
Original title: Case Report: Dose dependent intracranial response to sotorasib in KRASG12C-mutated lung cancer brain metastases.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is a report about a single patient, not a trial in many people.
The short version
When her usual dose stopped working, a higher dose brought her brain spots back under control.
What was studied. Doctors reported on a woman whose lung cancer had spread to her brain. Her cancer had a gene change called KRAS G12C, and she took a drug called sotorasib.
What they found. At first, the standard dose of 960 mg a day helped her brain and body spots. Later the brain spots grew again, and her doctors raised the dose to 1,920 mg. The brain spots then came back under control.
What this means, and what it doesn't
What it could mean: Cancer that spreads to the brain is hard to control. For a few people on this drug, a careful dose increase may be worth asking a doctor about.
What it doesn't mean: This is a report about a single patient, not a study. It does not show that the higher dose is safe or helpful for other people. A higher dose can also bring more side effects. This is not a cure, and it is not standard care today. Never change your own dose without your doctor.
Source: PubMed, October 17, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.